Article

E-cigarettes Not Found to Help Cancer Patients Quit Smoking

Patients who smoke both traditional and e-cigarettes less likely to quit than those who only smoke traditional cigarettes.

Patients who smoke both traditional and e-cigarettes less likely to quit than those who only smoke traditional cigarettes.

The rise in popularity of e-cigarettes has raised questions as to whether they aid smokers in quitting traditional cigarettes, however their use has not been found to help cancer patients kick the habit.

A recent study found that cancer patients who smoke both traditional cigarettes and e-cigarettes are more nicotine dependent, and equally or less likely to quit smoking traditional cigarettes than patients who only smoke traditional cigarettes. The study, which was published online September 22, 2014 in the journal Cancer, questions whether e-cigarettes are actually useful in helping cancer patients quit smoking altogether.

"Consistent with recent observations of increased e-cigarette use in the general population, our findings illustrate that e-cigarette use among tobacco-dependent cancer patients has increased within the past two years," said Jamie Ostroff, PhD, of the Memorial Sloan Kettering Cancer Center in a press release. "Controlled research is needed to evaluate the potential harms and benefits of e-cigarettes as a potential cessation approach for cancer patients.”

With the risks of persistent smoking, quitting the habit is especially important for cancer patients. Given the rise of e-cigarettes, health care providers question whether their usage aids or inhibits smoking cessation.

In an examination of clinical data on e-cigarette use among cancer patients, researchers studied 1074 cancer patients who are smokers that enrolled in a tobacco treatment program between 2012 and 2013.

The data illustrated a three-fold increase in e-cigarette use between 2012 and 2013, increasing from 10.6% to 38.5%. At the time of enrollment, e-cigarette users were found to be more nicotine dependent than patients who did not use e-cigarettes.

Additionally, the e-cigarette users were more likely to have unsuccessfully tried to quit in the past, and were more likely to be diagnosed with lung or head and neck cancers.

At follow-up, e-cigarette users were found to be equally as likely to still be smoking as traditional smokers. The 7-day abstinence rates were 44.4% for e-cigarette users versus 43.1% for non-users, excluding patients lost to follow-up.

The authors stress that the study had several limitations and additional research is required.

“In the meantime, oncologists should advise all smokers to quit smoking traditional combustible cigarettes, encourage use of FDA-approved cessation medications, refer patients for smoking cessation counseling, and provide education about the potential risks and lack of known benefits of long-term e-cigarette use,” Ostroff said.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards